Serum NSE level and disability progression in multiple sclerosis

Noseworthy, 2000, Multiple sclerosis, N Engl J Med, 343, 938, 10.1056/NEJM200009283431307 Renoux, 2011, Natural history of multiple sclerosis: long-term prognostic factors, Neurol Clin, 29, 293, 10.1016/j.ncl.2011.01.006 Comabella, 2014, Body fluid biomarkers in multiple sclerosis, Lancet Neurol, 13, 113, 10.1016/S1474-4422(13)70233-3 Cunningham, 1994, Serum neurone-specific enolase concentrations in patients with neurological disorders, Clin Chim Acta Int J Clin Chem, 230, 117, 10.1016/0009-8981(94)90264-X Sladkova, 2011, Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing–remitting course of disease and after clinical isolated syndrome, Neurol Res, 33, 415, 10.1179/016164110X12816242542535 Hein, 2008, Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis, Neurosci Lett, 436, 72, 10.1016/j.neulet.2008.02.064 Koch, 2007, Plasma S100beta and NSE levels and progression in multiple sclerosis, J Neurol Sci, 252, 154, 10.1016/j.jns.2006.11.012 Marangos, 1981, Brain levels of neuron-specific and nonneuronal enolase in Huntington's disease, J Neurochem, 37, 1338, 10.1111/j.1471-4159.1981.tb04687.x Poser, 1983, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, 13, 227, 10.1002/ana.410130302 Polman, 2011, Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria, Ann Neurol, 69, 292, 10.1002/ana.22366 Kurtzke, 1983, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 33, 1444, 10.1212/WNL.33.11.1444 Roxburgh, 2005, Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity, Neurology, 64, 1144, 10.1212/01.WNL.0000156155.19270.F8 R Development Core Team, 2013 Van Engelen, 1992, Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid, Clin Chem, 38, 813, 10.1093/clinchem/38.6.813 Nygaard, 1998, Neuron-specific enolase concentrations in serum and cerebrospinal fluid in patients with no previous history of neurological disorder, Scand J Clin Lab Invest, 58, 183, 10.1080/00365519850186562 Schaf, 2005, S100B and NSE serum levels in patients with Parkinson's disease, Parkinsonism Relat Disord, 11, 39, 10.1016/j.parkreldis.2004.07.002 Casmiro, 2005, Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population, Eur J Neurol Off J Eur Fed Neurol Soc, 12, 369 Lassmann, 2005, Multiple sclerosis pathology: evolution of pathogenetic concepts, Brain Pathol, 15, 217, 10.1111/j.1750-3639.2005.tb00523.x Lucchinetti, 2011, Inflammatory cortical demyelination in early multiple sclerosis, N Engl J Med, 365, 2188, 10.1056/NEJMoa1100648 Lassmann, 2012, Progressive multiple sclerosis: pathology and pathogenesis, Nat Rev Neurol, 8, 647, 10.1038/nrneurol.2012.168 Jauch, 2006, Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study, Stroke J Cereb Circ, 37, 2508, 10.1161/01.STR.0000242290.01174.9e Chabok, 2012, Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury, J Trauma Acute Care Surg, 72, 1654, 10.1097/TA.0b013e318246887e